T2011-143 SAGE, Self-Administered Gerocognitive Examination, is a test used for early identification of mild cognitive impairment (MCI) to identify patients or research participants with symptoms of Alzheimer’s or other dementia-related diseases.
Patients benefit from early-stage treatment strategies that can slow the progression of dementia-related diseases. Other methods are unable to differentiate normal aging from MCI, but it is important to distinguish between the two since patients most benefit from early-stage treatments. Therefore, there is an immense need for a cognitive assessment tool that screens/case finds individuals to identify MCI and early-stage dementia-related diseases.
The SAGE test, developed by Ohio State neurologist Dr. Douglas Scharre, is a self-administered assessment tool that can be downloaded, printed, and taken via pen to paper. This allows examination at a person’s home, in a physician’s office, or virtually anywhere. SAGE identifies cognitive impairment in its earliest stages. By detecting subtle cognitive impairments and being sensitive to changes over time, SAGE differentiates normal aging from MCI. Early identification of cognitive impairment makes it easier to find research participants at early and pre-dementia stages to evaluate research therapies.
- Early patient identification for further evaluation of symptoms
- Research participant identification for clinical trials
- Identification of post-treatment cognitive changes over time
- Able to differentiate normal aging from MCI
- Self-administration allows for convenient use when classifying patients and prescreening for drug trials
- Identifies patients in early stage of disease to enhance the benefits of disease-modifying treatments
- Provides a baseline for the future by detecting subtle cognitive impairments and being sensitive to changes over time
- Average test taking time is only 10-15 minutes
- Detects early dementia at least 6 months sooner than Mini-Mental State Examination (MMSE)
- Scharre, D. W. et al. Self-administered Gerocognitive Examination (SAGE): A Brief Cognitive Assessment Instrument for Mild Cognitive Impairment (MCI) and Early Dementia. (2010). Alzheimer Disease & Associated Disorders, 24(1), 64-71.
- Scharre, D. W. et al. Community Cognitive Screening Using the Self-Administered Gerocognitive Examination (SAGE). (2014). The Journal of Neuropsychiatry and Clinical Neurosciences, 26(4), 369-375.
- Scharre, D. W. et al. Self-Administered Gerocognitive Examination: longitudinal cohort testing for the early detection of dementia conversion. (2021). Alzheimer’s Research & Therapy, 13, 192.